Want to take quizzes and track your credits?
Nose and throat swab polymerase chain reaction (PCR) testing can miss up to 50% of coronavirus disease 2019 (COVID-19) cases, in part because the virus may have already cleared the upper respiratory tract. But by then, patients may have developed antibodies against the virus. An approach that combines rapid PCR and antibody testing could help physicians quickly diagnose more cases, a recent small study of hospitalized patients with suspected COVID-19 suggested.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
A University of Cambridge–led team analyzed previously collected data from the COVIDx Study, in which they clinically validated a simple amplification-based assay known as SAMBA II, a rapid PCR test to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Developed by a Cambridge spinoff company with partial US National Institutes of Health funding, the point-of-care (POC) test is now in routine clinical use in the UK.
You currently have no searches saved.